Iovance Biotherapeutics Reports Record Third Quarter 2026 Revenue of ~$122M, Business Achievements, and Corporate Updates
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Iovance Biotherapeutics Reports Record Third Quarter 2026 Revenue of ~$122M , Business Achievements, and Corporate Updates Total Revenue Increased ~80% and U.S. Amtagvi Revenue Increased ~77% Year-over-Year, and Gross Margin Increased to ~60% 24.6% Objective Response
How this was made
The 30-second read
Why it matters
The record revenue and lowered guidance are likely to support a bullish short‑term reaction, while upcoming regulatory milestones add longer‑term upside potential.
Market read
Iovance's strong Q3 results and pipeline progress make it a focal point for biotech investors and oncology‑focused funds.
What to watch
Regulatory timelines for MAA approvals in the UK, Switzerland and Brazil remain uncertain and could delay future growth.
Iovance Biotherapeutics Reports Record Third Quarter 2026 Revenue of ~$122M, Business Achievements, and Corporate Updates
Record product revenue, higher gross margin, sharply lower net loss, and reaffirmed full-year total product revenue guidance were supported by continued U.S. Amtagvi demand.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Total product revenue, three months ended September 30, 2026GAAP | $121.5M | ~22% | ~80% |
| Total revenue, three months ended September 30, 2026GAAP | 121,469 | – | – |
| Cost of sales, three months ended September 30, 2026GAAP | $48.03M | – | – |
| Research and development, three months ended September 30, 2026GAAP | 49,337 | decreased by ~16% | – |
| Selling, general, and administrative, three months ended September 30, 2026GAAP | 38,575 | – | – |
| Depreciation and amortization, three months ended September 30, 2026GAAP | 9,497 | – | – |
| Restructuring charges, three months ended September 30, 2026GAAP | - | – | – |
| Total costs and expenses, three months ended September 30, 2026GAAP | 145,437 | – | – |
| Loss from operations, three months ended September 30, 2026GAAP | (23,968) | – | – |
| Interest and other income, net, three months ended September 30, 2026GAAP | 2,311 | – | – |
| Net Loss before income taxes, three months ended September 30, 2026GAAP | −$21.66M | – | – |
| Income tax benefit (expense), three months ended September 30, 2026GAAP | (614) | – | – |
| Net Loss, three months ended September 30, 2026GAAP | −$22.27M | – | – |
| Net Loss Per Share of Common Stock, Basic and Diluted, three months ended September 30, 2026GAAP | $ (0.05) | – | – |
| Weighted Average Shares of Common Stock Outstanding, Basic and Diluted, three months ended September 30, 2026GAAP | 455,919 | – | – |
| Gross margin, third quarter 2026other | ~60% | – | – |
| Non-cash stock-based compensation included in cost of sales and operating expenses, three months ended September 30, 2026GAAP | $11.83M | – | – |
| Total product revenue, nine months ended September 30, 2026GAAP | $292.2M | – | – |
| Total revenue, nine months ended September 30, 2026GAAP | 292,212 | – | – |
| Cost of sales, nine months ended September 30, 2026GAAP | $134.1M | – | – |
| Research and development, nine months ended September 30, 2026GAAP | 170,675 | – | – |
| Selling, general, and administrative, nine months ended September 30, 2026GAAP | 116,796 | – | – |
| Depreciation and amortization, nine months ended September 30, 2026GAAP | 27,536 | – | – |
| Restructuring charges, nine months ended September 30, 2026GAAP | - | – | – |
| Total costs and expenses, nine months ended September 30, 2026GAAP | 449,128 | – | – |
| Loss from operations, nine months ended September 30, 2026GAAP | (156,916) | – | – |
| Interest and other income, net, nine months ended September 30, 2026GAAP | 6,861 | – | – |
| Net Loss before income taxes, nine months ended September 30, 2026GAAP | −$150.1M | – | – |
| Income tax benefit (expense), nine months ended September 30, 2026GAAP | 1,424 | – | – |
| Net Loss, nine months ended September 30, 2026GAAP | −$148.6M | – | – |
| Net Loss Per Share of Common Stock, Basic and Diluted, nine months ended September 30, 2026GAAP | $ (0.34) | – | – |
| Weighted Average Shares of Common Stock Outstanding, Basic and Diluted, nine months ended September 30, 2026GAAP | 442,683 | – | – |
| Non-cash stock-based compensation included in cost of sales and operating expenses, nine months ended September 30, 2026GAAP | $34.84M | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| U.S. Amtagvi revenuecontinued U.S. Amtagvi demand | ~$102 million | ~12% | ~77% |
| Global Proleukin revenueGlobal Proleukin revenue was reported for 3Q26. | ~$20 million | – | – |
Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.
Full Year 2026 outlook
- Revenue$410 to $420 million in total product revenue
- Gross marginImprovements in gross margin are expected to continue, excluding occasional one-time items.
- NoteAt least 110 ATCs expected to be active by the end of 2026.
- NotePotential approval in the UK by 1Q27.
- NotePotential MAA approval by Swissmedic expected in 1Q27.
- NoteAn MAA for Amtagvi in advanced melanoma to ANVISA is planned in 2027.
- NoteAn MAA resubmission for Amtagvi to the European Medicines Agency is on track for 2027.
- NoteAn sBLA for lifileucel based on IOV-LUN-202 Cohorts 1 and 2, with a target of approximately 80 patients, is planned in 2027.
- NotePOSI TIL ITY enrollment began this month with a target of 80 patients.
- NoteIovance plans to initiate OP TIL ISM in 2027.
- NoteCurrent cash is expected to fund operations well into 2029.
What drove it
- Total product revenue was driven by continued U.S. Amtagvi demand.
- Gross margin reflected higher Amtagvi sales volume and effective internal cost optimization programs spanning all of product production.
- R&D expenses decreased by ~16% compared to 2Q26, driven by operational efficiencies.
- The ATC network has grown to more than 100 U.S., Canadian, and Australian ATCs, and community ATCs represent a third of the network.
- Amtagvi turnaround time for the majority of lots is about 30 days or less.
- IOV-LUN-202 reported a 24.6% ORR in 69 patients with non-squamous mNSCLC, including two unconfirmed responses.
- The biomarker-enriched subgroup within IOV-LUN-202 achieved a 59.1% ORR.
- The confirmed ORR in UPS and DDLPS increased to 55.6% (5/9).
- TILVANCE-301 enrollment is accelerating at more than 80 sites in the U.S., Canada, Europe, and Asia-Pacific.
Concerns
- The company remained loss-making, with Net Loss of $ (22,271) in the third quarter and $ (148,631) for the nine months ended September 30, 2026.
- Gross-margin improvement is expected to exclude occasional one-time items.
- IOV-LUN-202 Cohorts 1 and 2 are completing enrollment, while independent review committee assessments, FDA discussions, and other pre-submission activities remain ongoing.
- Clinical results may not be confirmed or reflected in independent review assessments or final analyses, according to the company’s forward-looking statements.
- The company cited risks related to commercialization, ATC expansion, manufacturing capacity, payor coverage, revenue recognition, regulatory approvals, clinical enrollment, and potential unanticipated expenses.
What to watch
- Achievement of the $410 to $420 million full-year 2026 total product revenue guidance range.
- Whether gross-margin improvements continue as Amtagvi sales volume rises.
- Expansion to at least 110 active ATCs by the end of 2026 and growth in community ATCs.
- Completion of IOV-LUN-202 Cohorts 1 and 2 and planned 2027 sBLA preparation.
- Enrollment in POSI TIL ITY and planned initiation of OP TIL ISM in 2027.
- Potential UK and Switzerland approvals by 1Q27.
- SARATOGA enrollment in UPS and DDLPS and durability of reported responses.
- Progress of TILVANCE-301, including its early interim analysis based on ORR.
Balance sheet and cash flow
- Cash, cash equivalents, and investments as of September 30, 2026: $ 376,320; December 31, 2025: $ 296,980.
- Restricted cash as of September 30, 2026: $ 6,018; December 31, 2025: $ 5,980.
- Cash position as of September 30, 2026: ~$382 million.
- Total assets as of September 30, 2026: $ 991,214; December 31, 2025: $ 913,170.
- Stockholders’ equity as of September 30, 2026: $ 812,662; December 31, 2025: $ 698,583.
- Current cash is expected to fund operations well into 2029.
Analysis
Iovance reported a second consecutive record quarter, with total product revenue of $ 121,469 for the three months ended September 30, 2026, versus $ 67,455 a year earlier. The release characterized this as an increase of ~80%, with U.S. Amtagvi revenue of ~$102 million up ~77% year-over-year and ~12% from 2Q26. Global Proleukin revenue was ~$20 million. Management attributed the commercial performance to continued U.S. Amtagvi demand and said the ATC network had grown to more than 100 sites across the U.S., Canada, and Australia.
Margin and cost trends improved. Gross margin was ~60%, compared with 56% in 2Q26, reflecting higher Amtagvi volume and internal product-production cost optimization. R&D expense was 49,337 for the quarter, down from 75,174 a year earlier and described as down ~16% from 2Q26. Total costs and expenses declined to 145,437 from 162,356, reducing loss from operations to (23,968) from (94,901) and net loss to $ (22,271) from $ (91,253).
For the nine months ended September 30, 2026, total product revenue was $ 292,212, compared with $ 176,731 in the prior-year period. Despite the revenue growth and lower R&D expense, the company reported a nine-month Net Loss of $ (148,631). Balance-sheet liquidity consisted of $ 376,320 of cash, cash equivalents, and investments plus $ 6,018 of restricted cash at September 30, 2026. The company said its cash position was ~$382 million and expected current cash to fund operations well into 2029.
Management remained on track toward $410 to $420 million of full-year 2026 total product revenue and expects gross-margin improvement to continue, excluding occasional one-time items. Operational milestones include a target of at least 110 active ATCs by the end of 2026, potential UK and Swiss approvals by 1Q27, and multiple clinical programs advancing toward enrollment, regulatory engagement, or planned 2027 submissions. The principal execution items are sustaining Amtagvi demand and margin gains while advancing IOV-LUN-202, POSI TIL ITY, SARATOGA, and TILVANCE-301 through their stated clinical and regulatory milestones.
Management, verbatim
Third quarter revenue reached a new record of ~$122 million with our highest gross margin ever, driven by continued U.S. Amtagvi demand.
Frederick Vogt, Ph.D., J.D., Interim Chief Executive Officer and President
We remain on track to achieve our full-year 2026 total revenue guidance of $410 to $420 million and recently marked the tremendous milestone of more than 1,000 commercially treated Amtagvi patients.
Frederick Vogt, Ph.D., J.D., Interim Chief Executive Officer and President
Not in the filing
stated, not guessed- Prior full-year outlook was not provided; therefore, comparison of actual results with prior guidance is unavailable.
- Operating cash flow was not reported.
- Free cash flow was not reported.
- Debt was not reported.
- Share repurchases were not reported.
- Dividends were not reported.
- Non-GAAP net income or loss was not reported.
- Non-GAAP EPS was not reported.
- A GAAP gross-margin figure was not reported.
- Guidance for operating expenses and tax rate was not reported.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
The 8‑K filing provides the company's first official quarterly financials and updates on multiple clinical programs.
Ticker impact
Iovance Biotherapeutics filed an 8‑K reporting record Q3 2026 revenue of ~$122 M and lowered its full‑year guidance of $410‑$420 M.
likely upside as investors price in the strong revenue growth and lowered guidance.
The filing is the first public disclosure of the quarterly results and guidance, providing fresh material that can move the share price.
Market effects
Biotech sector may benefit from the demonstrated efficacy of TIL therapies and the company's fast‑growing commercial sales.
U.S. biotech investors could see increased interest, while European markets may watch upcoming MAA submissions.
Positive data on lifileucel could influence global oncology‑focused funds.
Counterpoint
If the market has already priced in the revenue surge, the stock may face a short‑term pullback.
Key entities
- CompanyIovance Biotherapeutics
Developer of lifileucel TIL therapies.
